Hainsworth JD, et al. Target Oncol. (2016) cited as Ref 633 in DOI: 10.1038/s41392-020-0110-5 (Q9896)
Revision as of 22:05, 20 May 2020 by Admin (talk | contribs) (Created claim: Property:P93: A randomized open-label phase 2 study of the CXCR4 inhibitor LY2510924 in combination with sunitinib versus sunitinib alone in patients with metastatic renal cell carcinoma (RCC), #quickstatements; #tempo...)
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Hainsworth JD, et al. Target Oncol. (2016) cited as Ref 633 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Hainsworth JD
0 references
2016
0 references
Target Oncol.
0 references
11
0 references
A randomized open-label phase 2 study of the CXCR4 inhibitor LY2510924 in combination with sunitinib versus sunitinib alone in patients with metastatic renal cell carcinoma (RCC) (English)
0 references
